Spotting a conflict of interest in medicine requires neither generalised suspicion nor conspiracy theory: it requires consulting public registers. In the United States, the Sunshine Act obliges manufacturers to declare every payment to a physician in the Open Payments database; in France, the Transparence Santé database records the links between professionals and industry. Checking who funds a practitioner's training, their speaking fees, or their consulting contracts takes only a few minutes — and this article explains how, without ever confusing a link of interest with wrongdoing.
A useful definition. A conflict of interest exists when a secondary interest — most often financial — is liable to influence a professional judgement that should rest on the patient's interest alone. It is a structural risk, not proof of corruption: a physician may have links and remain upright. Spotting the conflict means identifying the situation, not delivering a verdict.
The first reflex is documentary, not intuitive. Several countries now require the public declaration of financial links between industry and health professionals, and these data are available to anyone, free of charge.
Finding a payment in one of these databases does not mean a physician is bought. It means a link exists and deserves to be taken into account when assessing a recommendation, especially if it concerns precisely the funder's product. This is exactly what ProPublica's cross-referencing of declared payments and Medicare prescribing data made measurable: physicians who had received a payment linked to a given drug prescribed it more than their non-paid colleagues.
An often-overlooked point of vigilance concerns training. Part of continuing medical education — congresses, symposia, teaching materials — has historically been funded, directly or indirectly, by industry. This does not make such training necessarily biased, but it introduces a risk of orientation: the choice of topics, speakers, and featured products may, at the margin, reflect the funder's interest. The effect has been measured even on modest benefits: a study published in JAMA Internal Medicine in 2016 showed that a single sponsored meal, worth on average less than $20, was associated with a higher prescribing rate of the promoted brand-name drug.
To spot it, a few simple questions suffice: who funds this congress or module? Does the speaker declare their links with the manufacturers of the products they discuss? Does the training compare several therapeutic options, or does it foreground a single brand? Transparent training owns its funding and declares the links; opacity, by contrast, is the real warning sign. Independent training schemes exist precisely to reduce this dependence.
U.S. legal actions against several major laboratories have brought to light a recurring technique: the funding of medical key opinion leaders. These are recognised experts, paid as speakers or consultants, whose word influences the prescribing practices of an entire specialty. The practice is not illegal in itself — an expert can legitimately be paid — but it becomes problematic when their visibility serves to promote an unvalidated use.
To spot this lever, one can cross-reference sources: does the expert who is highly present in the media or at congresses on a given treatment appear in the transparency databases as a beneficiary of that treatment's manufacturer? Are their positions relayed by content that conceals these links? Here again, the financial link does not invalidate the expertise; it invites seeking a second, independent source before adopting a conclusion. A systematic review published in 2021 in the Annals of Internal Medicine, surveying thirty-six studies, concludes that there is a consistent association between industry payments and increased prescribing — a coherent body of evidence, even if direct causality remains, by nature, difficult to isolate.
Every serious study, guideline, or expert opinion now includes a "conflicts of interest" or "declaration of links" section. Reading it is part of assessing medical information, just as much as its results. An empty declaration is no more reassuring than a full one: what matters is its coherence with the subject treated.
Two more discreet mechanisms deserve mention, since they escape the simple reading of a declaration. The first is publication bias: trials with negative results are less often published. By comparing the antidepressant trials registered with the FDA to those actually appearing in the literature, Erick Turner and colleagues showed, in 2008, that selective publication inflated the class's apparent efficacy by about 32%. The second is ghostwriting: articles drafted by industry-commissioned providers, then signed by academics — a long-documented practice in the literature on the "ghost management" of medical publication.
This is the decisive point, and the one where many slip. Spotting a conflict of interest is a tool of discernment, not a licence to reject everything. That a laboratory funded the training around a drug, or paid its promoters, says nothing about the molecule's own effectiveness: a vaccine remains effective, an antibiotic remains vital, even if the marketing surrounding them may have been condemned. Confusing the two levels — commercial practice and therapeutic value — is exactly the error that anti-vaccine disinformation exploits.
The right use is the reverse: spotting a conflict triggers an additional check, not an automatic conclusion. One looks for an independent source, examines the full body of data, and distinguishes what has been judged (a misleading promotion, a withholding of data) from what has not (the principle of treating). Demanding transparency is defending evidence-based medicine — not rejecting it.
Is a physician with industry links necessarily corrupt? No. A link of interest is a risk factor, not wrongdoing. Many experts collaborate legitimately with industry — research, clinical trials — while keeping their integrity. The conflict must be declared and taken into account, not turned into an automatic accusation.
Where can you check a health professional's financial links? In the United States, the CMS Open Payments database is searchable online by physician name. In France, the public Transparence Santé site records the benefits and agreements declared by companies. For study authors, the declaration of links is generally found at the end of the article or guideline.
Does spotting a conflict of interest mean the treatment should be refused? Absolutely not. The conflict concerns the reliability of the information and its promotion, not the value of the care. The right answer is to seek an independent assessment of the treatment, not to reject it on the grounds that an interested party promoted it.
These individual reflexes fit within a broader file: that of the sector's commercial practices, as established by public convictions and fines. To understand the recurring patterns — off-label marketing, funding of prescribers, regulatory capture — without tipping into generalised distrust, see our investigation into the convictions and fines of the pharmaceutical industry.
To go further, the mini-investigation Big Pharma — The Documented Corruption gathers these facts, piece by piece, from public legal acts and settlement agreements alone — in order to distinguish documented commercial fraud from the real value of treatments.
No. A link of interest is a risk factor, not wrongdoing. Many experts collaborate legitimately with industry — research, clinical trials — while keeping their integrity. The conflict must be declared and taken into account, not turned into an automatic accusation.
In the United States, the CMS Open Payments database is searchable online by physician name. In France, the public Transparence Santé site records the benefits and agreements declared by companies. For study authors, the declaration of links is generally found at the end of the article or guideline.
Absolutely not. The conflict concerns the reliability of the information and its promotion, not the value of the care. The right answer is to seek an independent assessment of the treatment, not to reject it on the grounds that an interested party promoted it.
Dossier : Big Pharma & souveraineté alimentaire
MINI15: Big Pharma — La Corruption Documentée
Accueil · Collection · Journal · Dossiers · Sources